The present invention provides for fusion tags of 20 to 50 amino acids having a sequence as given in Figure 1, fusion tags sharing homology with these fusion tags, or hybrid fusion tags comprising sequences of Figure 1. The invention further provides an expression vector system comprising a fusion tag of the inventi...

The present disclosure relates to providing an engineered CHO cell line wherein the two essential metabolic genes are knocked out. Particularly, the present invention relates to a double knockout CHO cell line (DHFR-/- and GS-/-) with disrupted Dihydrofolate Reductase (DHFR) and Glutamine Synthetase (GS) genomic loc...

The present invention relates to succinic acid and its derivative(s) of Formula (I), their pharmaceutically acceptable salts, polymorphs, solvates, hydrates, co-crystals, isomers and solvates thereof as an active pharmaceutical ingredient for the treatment of haematological disorder(s). The present invention further...

The present invention relates to an automated integrated continuous bioprocess system and bioprocess that are capable of continuously producing therapeutic protein in an uninterrupted manner and scalable from laboratory to manufacturing scale. The present invention provides an automated integrated continuous bioproc...

The present disclosure relates to a bio-manufacturing process that enables continuous production of a therapeutic protein with reduced heterogeneity. The bio-manufacturing process disclosed herein utilizes a multi column chromatography system that performs the unit operations of reducing heterogeneity in a therapeut...

The present invention relates to an automated integrated continuous bioprocess system and bioprocess that are capable of continuously producing therapeutic protein in an uninterrupted manner and scalable from laboratory to manufacturing scale. The present invention provides an automated integrated continuous bioproc...

The present disclosure relates to an analog of glucagon-like peptide-1 (glp-1)receptor agonist. The present disclosure provides analogs of glucagon-like peptide-1 (glp-1) receptor agonist wherein, the amino acid at position 2 of the 5 glucagon-like peptide-1 (glp-1)receptor agonist is replaced with D-Alanine. The an...

The present invention relates to pharmaceutical composition comprising GLP-1 analogue its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates thereof. The present invention further relates to a liquid composition comprising GLP-1 analogue or its pharmaceutically acc...

The present invention encompasses compounds and composition that inhibit Src kinase and methods of treating or preventing disorders associated therewith. In some embodiments, the invention encompasses compositions and combinations of agents that act synergistically inhibit the growth of cancer cells and particularly...

The present invention generally relates to a process for the preparation of plecanatide. Specifically, the present invention relates to an improved process for preparation of plecanatide using a non-linear solid phase peptide synthesis. In particular, the process for preparation of plecanatide of the present inventi...

The present invention generally relates to a process for the preparation of plecanatide. Specifically, the present invention relates to an improved process for preparation of plecanatide using a non-linear solid phase peptide synthesis. In particular, the process for preparation of plecanatide of the present inventi...

The present invention relates to pharmaceutical composition comprising HER2 antibody, its analogues or complexes. The present invention further relates to a liquid formulation comprising HER2 antibody, its analogues or complexes and processes for preparing the same and methods of using it. More particularly, the pre...

The present invention relates to the processes for preparing glucagon-like peptide-1 (glp-1) receptor agonists and their analogs. The present invention further relates to processes for preparing liraglutide, D-liraglutide, semaglutide and D-semaglutide. The present invention specifically relates to processes for pre...

The present disclosure relates to a plant-based egg substitute. The present disclosure provides a process for extraction of protein isolate from mung bean that can serve as a plant-based egg substitute and that can help reduce or eliminate undesirable odour usually found in the mung bean protein isolate. ...

The present invention provides a process for an in line cleaning in place (CIP) of an alternating tangential flow (ATF) filter in a filtration module, the filtration module being in communication with a bioreactor. The process comprises: flowing a dilute NaOH through the ATF filter, the dilute NaOH being 0.1 to 0.5 ...

The present invention provides a composition comprising of unique combination of the anti-human interleukin 6 (IL-6) receptor monoclonal antibodies with buffer, viscosity reducing agent, stabilizer / isotonic agent and surfactants, which is stable, has isotonicity pH 6.0 and viscosity range suitable for subcutaneous...